Sponsor content
219 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EVRYSDI risdiplam 5 mg tablet blister pack.
-
Jan-2026Prescription medicine evaluationActive ingredient: ocrelizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OCREVUS SC ocrelizumab 920 mg/23 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 3 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 9 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Medication transfer set.
-
Australian Public Assessment Report (AusPAR)ITOVEBI (inavolisib), in combination with palbociclib and fulvestrant, is for the treatment of adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine therapy.
-
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VABYSMO faricimab 120 mg/mL solution for injection in a pre-filled syringe.